The latest presentation totally negates all our worries. States trial was carefully monitored and only 3percent of unusable data!!!!!!!!!!! Maybe suspension is to get us so hyped up if result is good stock Bsolutely flies as we have had five days to worry. Not a bad strategy to push up the price. They would have been disappointed that sleep result did nothing to share price!
”Revised US paediatric study, SMARTCOUGH-C-2- Double-blind, prospective study- Details on www.clinicaltrials.gov (NCT03392363)- Recruitment complete, 1,470 patients aged 29 days to 12 years- Top-tier US hospitals: Massachusetts General Hospital, Cleveland Clinic & Texas Children’s Hospital- Upgraded recording app and training, on-site data verification- Centralised, independent clinical adjudication, less subjective casedefinitions- Audio QA showing high quality audio (<3% found to be unacceptable)- Top-line results in Q3 CY2018 “
